Havas and BrightInsight Target Pharma’s $500B+ Adherence Crisis

NEW YORK, NY – February 26, 2026 – Global communications leader Havas Health Network has forged an exclusive, strategic partnership with digital health platform BrightInsight to confront one of the most persistent and costly challenges in modern medicine: patient non-adherence. The alliance designates Havas Health as BrightInsight’s single global agency partner, creating a first-of-its-kind offering that combines high-level healthcare strategy with a compliant, scalable technology platform designed to keep patients on their prescribed therapies.

This collaboration directly targets the gap between a prescription being written and a therapy achieving its intended real-world effectiveness. By deploying an AI-enabled, regulatory-ready digital platform across the 60-plus countries Havas Health supports, the partnership aims to curb staggering financial losses for the biopharma industry and, more importantly, improve health outcomes for millions of patients worldwide.

The Staggering Cost of the Patient Problem

The financial and clinical toll of patients failing to take their medications as prescribed is immense. While the partnership announcement cites an industry estimate of approximately $500 billion in annual losses, independent research suggests the figure is even higher. A 2016 report from Capgemini Consulting and HealthPrize Technologies estimated that the pharmaceutical industry loses as much as $637 billion in global revenue each year due to non-adherence for chronic illnesses.

Beyond industry revenue, the impact on the broader healthcare system is catastrophic. In the United States alone, poor adherence is linked to between $100 billion and $300 billion in avoidable healthcare costs from complications and hospitalizations. The human cost is even more dire, with medication non-adherence contributing to an estimated 125,000 deaths annually in the U.S. and accounting for up to a quarter of all hospital admissions.

The reasons behind this crisis are multifaceted. The World Health Organization (WHO) has identified five key dimensions influencing adherence, including socioeconomic factors, healthcare system inefficiencies, therapy complexity, condition-related issues, and patient-related behaviors. Simple forgetfulness is a leading cause, but other significant barriers include managing side effects, low health literacy, and the financial burden of prescriptions. As treatments for chronic conditions like diabetes, heart disease, and mental health become more complex and lifelong, ensuring patients remain on therapy is the primary barrier to clinical success.

A Converged Solution of Strategy and Technology

The Havas-BrightInsight alliance proposes a deeply integrated solution to this complex problem. It combines Havas Health's expertise in mapping the patient journey and activating engagement with BrightInsight's configurable, “always-on” technology. The goal is to create a seamless support system that accompanies the patient long after they leave the pharmacy.

BrightInsight's platform has demonstrated a tangible impact, showing in one case study with a top biopharma partner the ability to reduce long-term therapy discontinuation by four percentage points and increase adherence by four percentage points over traditional patient support programs. This is achieved through tools like patient companion apps, digital-first support programs, and regulated Software as a Medical Device (SaMD) solutions.

“Our clients are no longer asking if they should go digital, but how they can do so without reinventing the wheel for every market and every brand,” said Jeff Hoffman, Chief Development Officer at Havas Health Network. “By integrating BrightInsight's platform into our core offering, Havas Health is moving beyond traditional communications. We are now providing our clients with a pre-vetted, regulatory-ready engine that ensures a patient's experience with a brand is as meaningful and reliable as the therapy itself.”

A critical component of the offering is its compliance-focused architecture. BrightInsight’s platform is built to navigate the complex and varied regulatory landscapes of global markets, including the stringent requirements of the U.S. Food and Drug Administration (FDA) and the European Union’s Medical Device Regulation (MDR). This “compliant by design” approach de-risks the process for pharmaceutical companies, allowing them to rapidly launch and scale digital health solutions with confidence in their data privacy, security, and regulatory standing.

The Evolving Agency in a Digital Health Era

This partnership marks a significant strategic evolution for Havas Health, reflecting its broader “Converged” strategy of fusing human insight with advanced technology. It signals a definitive move for the communications network beyond traditional advertising and marketing into the realm of integrated, technology-driven health solutions. By securing an exclusive global partnership with a leading platform like BrightInsight, Havas differentiates itself in a competitive landscape that includes other major networks like Publicis Health and Omnicom Health Group, which are also expanding their digital capabilities.

The alliance represents a broader industry trend where the lines between marketing agencies and health technology companies are blurring. As pharmaceutical clients increasingly demand measurable return on investment and tangible improvements in patient outcomes, agencies are compelled to provide solutions that have a direct clinical and commercial impact. This partnership allows Havas to offer a standardized yet configurable infrastructure that can optimize and unify the patient support experience at a global scale.

Redefining Global Patient Engagement

At its core, the collaboration is about transforming the patient’s daily life and relationship with their therapy. With treatment regimens becoming more complex and a growing number of patients managing chronic illnesses, the need for continuous, personalized support has never been greater. The integrated platform aims to deliver just that, providing everything from medication reminders and educational content to side-effect tracking and telehealth connections.

“This partnership with Havas Health enables BrightInsight to bridge the gap between digital innovation and commercial scale,” said Kal Patel, MD, CEO and Co-Founder of BrightInsight. “By aligning our platform with Havas' deep strategic influence and global reach, we can ensure that digital health solutions are successfully integrated into the brand's DNA and the patient's daily life, driving measurable impact for our partners and better outcomes for patients worldwide.”

For biopharma companies, the partnership promises a clear path to demonstrating value beyond the pill and building long-term brand trust. For patients, it offers the potential for empowerment, giving them the digital tools needed to manage their health more effectively. And for healthcare providers, it can provide valuable data insights to support clinical decisions and facilitate more proactive care. This strategic alignment underscores a commitment to not only addressing a multi-billion-dollar market failure but also making a meaningful difference in the lives of patients across the globe.